Intel®, Cancer Research UK and Imperial College London Celebrate Supercomputing Successes in the UK

IntelToday Cancer Research UK and Imperial College London outlined the fundamental importance of High Performance Computing to their future science and research strategies. The two organisations described how Intel® High Performance Computing (HPC) solutions are enabling them to drive forward their research, which will lead to future scientific breakthroughs.

Imperial College London currently spends over £1,000 000 on its HPC programme. "HPC allows us to simulate events that would be impossible or very difficult to measure experimentally," stated Simon Burbidge, High Performance Computing Co-ordination Manager at Imperial College London. "For example, it is very difficult to reach the kind of temperatures such as those within the sun or plasmas in the real world, but by using HPC we can perform simulations to predict the results and thus tune the experiments. Another area of research at Imperial College London is using HPC to model blood flows in human arteries, to drive insights into the conditions leading to heart and circulatory disease. It is also helping us to do better research at lower cost, for example where simulations can replace some of the wind tunnel tests used in automobile design."

Peter McCallum, Head of IT & Scientific Computing at Cancer Research UK's Cambridge Research Institute described the benefits that HPC has brought to his organisation, "Through HPC we can effectively sequence a human’s whole DNA. Medical units in hospitals may soon need HPC access to enable them to track disease. We believe that in the future there will be local access to HPC with a local scientific computing team in all biological science organisations. What happened in physics and chemistry twenty years ago is now happening in biology."

Sean McGuire, Director Strategic Government Programs HPC EMEA at Intel stated, "HPC is an added direction for Intel. Through the Intel® Many Integrated Core (MIC) architecture we can achieve more compute power than would have been possible previously. It is an architecture that is designed for highly parallel workloads. We believe that it is an indication of where computing is going."

Robert Maskell, Head of HPC for Intel in the UK added, "Analysts have been telling us for a while that HPC is now mainstream, I think it is even further along the curve than that. It is pervasive. It is difficult to think of any manmade object which has not been created without being touched by HPC during the design process. HPC has become one of the fundamental building blocks for science. Researchers are being deluged by floods of data. The question they are asking is how can they cost effectively process and securely store that data. We believe Intel's Xeon range of processors deliver the energy-efficient performance that will allow researchers to draw ever quicker results and conclusions from their science."

Intel Corporation announced plans earlier this year to deliver new products based on the Intel® Many Integrated Core (MIC) architecture that will create platforms running at trillions of calculations per second, while also retaining the benefits of standard Intel processors. Targeting high-performance computing segments such as exploration, scientific research and financial or climate simulation, the first product, codenamed "Knights Corner", will be made on Intel's 22-nanometer manufacturing (nm) process - using transistor structures as small as 22 billionths of a meter - and will use Moore's Law to scale to more than 50 Intel processing cores on a single chip. While the vast majority of workloads will still run best on award-winning Intel® Xeon® processors, Intel® MIC architecture will help accelerate select highly parallel applications.

Industry design and development kits codenamed "Knights Ferry" are currently shipping to select developers, and beginning in the second half of 2010, Intel will expand the program to deliver an extensive range of developer tools for Intel MIC architecture.

Related news articles:

About Intel
Intel (NASDAQ: INTC), the world leader in silicon innovation, develops technologies, products and initiatives to continually advance how people work and live. Additional information about Intel is available at www.intel.com/pressroom and blogs.intel.com.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...